Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat

Epilepsia

Volumn 51, Issue 8, 2010, Pages 1543-1551

  Kalinichev, Mikhail ^a   Bradford, Andrea ^a   Bison, Silvia ^b   Lucas, Adam ^a   Sartori, Ilaria ^b   Garbati, Nicoletta ^b   Andreetta, Filippo ^b   Bate, Simon ^a   Austin, Nigel E ^a   Jones, Declan N C ^a   Read, Kevin D ^b,c   Alvaro, Giuseppe ^b   Large, Charles H ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GSK   (Italy)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Lamotrigine; Neurokinin 1; Seizure; Sodium channel; Vofopitant

Indexed keywords

2 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL] 7 METHYL 1,7 DIAZASPIRO[4.4]NONAN 6 ONE; 5 (2,3 DICHLOROPHENYL) 6 (FLUOROMETHYL) 2,4 PYRIMIDINEDIAMINE; 5 [4 [[(2 FLUOROPHENYL)METHYL]OXY]PHENYL]PROLINAMIDE; GABAPENTIN; GR 226206; GW 273225; LAMOTRIGINE; N [[2 (METHYLOXY) 5 [5 (TRIFLUOROMETHYL) 1H TETRAZOL 1 YL]PHENYL]METHYL] 2 PHENYL 3 PIPERIDINAMINE; SODIUM CHANNEL; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VALPROIC ACID; VOFOPITANT; ANTICONVULSIVE AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; GENERALIZED EPILEPSY; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; ELECTROSHOCK; METABOLISM; SEIZURES; SPRAGUE DAWLEY RAT;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROSHOCK; MALE; NEUROKININ-1 RECEPTOR ANTAGONISTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SODIUM CHANNELS; TETRAZOLES;

EID: 77955310500     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02482.x     Document Type: Article

References (39)

1. Alvaro G, Di Fabio R 2007) Neurokinin 1 receptor antagonists - current prospects. Curr Opin Drug Discov Devel 10:613 621.
2. Aosaki T, Kawaguchi Y 1996) Actions of substance P on rat neostriatal neurons in vitro. J Neurosci 16:5141 5153.
3. Beaujouan JC, Torrens Y, Saffroy M, Kemel ML, Glowinski J 2004) A 25 year adventure in the field of tachykinins. Peptides 25:339 357.
4. Bellmann R, Humpel C, Krause JE, Marksteiner J, Saria A, Sperk G 1991) Differential changes in mRNAs encoding for preprotachykinin A and B after kainic acid-induced seizures in the rat. Synapse 8:71 73.
5. Blomeley C, Bracci E 2008) Substance P depolarizes striatal projection neurons and facilitates their glutamatergic inputs. J Physiol 586:2143 2155.
6. Ebner K, Singewald N 2006) The role of substance P in stress and anxiety responses. Amino Acids 31:251 272.
7. Eggers AE 2007) Temporal lobe epilepsy is a disease of faulty neuronal resonators rather than oscillators, and all seizures are provoked, usually by stress. Med Hypotheses 69:1284 1289.
8. Galarraga E, Hernandez-Lopez S, Tapia D, Reyes A, Bargas J 1999) Action of substance P (neurokinin-1) receptor activation on rat neostriatal projection neurons. Synapse 33:26 35.
9. Gale K 1986) Role of the substantia nigra in GABA-mediated anticonvulsant actions. Adv Neurol 44:343 364.
10. Garant DS, Iadarola MJ, Gale K 1986) Substance P antagonists in substantia nigra are anticonvulsant. Brain Res 382:372 378.
11. Garant DS, Gale K 1987) Substantia nigra-mediated anticonvulsant actions: role of nigral output pathways. Exp Neurol 97:143 159.
12. Hargreaves R 2002) Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 63 (suppl 11 18 24.
13. Haut SR, Vouyiouklis M, Shinnar S 2003) Stress and epilepsy: a patient perception survey. Epilepsy Behav 4:511 514.
14. Jessell TM (1982) Substance P in nociceptive sensory neurons. Ciba Found Symp 91:225 248.
15. Jones RS, Olpe HR 1984) Activation of the noradrenergic projection from locus coeruleus reduces the excitatory responses of anterior cingulate cortical neurones to substance P. Neuroscience 13:819 825.
16. Jonker DM, Voskuyl RA, Danhof M 2007) Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 48:412 434.
17. Korotkova TM, Brown RE, Sergeeva OA, Ponomarenko AA, Haas HL 2006) Effects of arousal- and feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental area of the rat. Eur J Neurosci 23:2677 2685.
18. Kuo CC, Lu L 1997) Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br J Pharmacol 121:1231 1238.
19. Kwan P, Brodie MJ 2000) Early identification of refractory epilepsy. N Engl J Med 342:314 319.
20. Lamour Y, Dutar P, Jobert A 1983) Effects of neuropeptides on rat cortical neurons: laminar distribution and interaction with the effect of acetylcholine. Neuroscience 10:107 117.
21. Large CH, Webster EL, Goff DC 2005) The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181:415 436.
22. Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, Sartori I, Austin NE, Ruffo A, Jones DN, Alvaro G, Read KD 2009) The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res 85:96 106.
23. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH 2008) Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 49:888 897.
24. Litchfield JT Jr., Wilcoxon F 1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99 113.
25. Liu H, Cao Y, Basbaum AI, Mazarati AM, Sankar R, Wasterlain CG 1999) Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A 96:12096 12101.
26. Loiseau F, Le BC, Hamon M, Thiebot MH 2005) Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist in impulsive-related behaviour in rats. Psychopharmacology (Berl) 182:24 32.
27. Loscher W, Fassbender CP, Nolting B 1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 8:79 94.
28. Messenheimer JA 1995) Lamotrigine. Epilepsia 36 (suppl 2 S87 S94.
29. Newman D.B. 1995) Anatomy and neurotransmitters of brainstem motor systems. In Fahn S, Hallett M, Luders HO, Marsden CD (Eds) Negative motor phenomena. Lippincott-Raven Publications, Philadelphia, pp. 219 244.
30. Perucca E 2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695 714.
31. Ramaratnam S, Marson AG, Baker GA (2000) Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev Volume 3:.
32. Rupniak NM, Carlson EJ, Shepheard S, Bentley G, Williams AR, Hill A, Swain C, Mills SG, Di SJ, Kilburn R, Cascieri MA, Kurtz MM, Tsao KL, Gould SL, Chicchi GG 2003) Comparison of the functional blockade of rat substance P (NK1) receptors by, and NKP 608 Neuropharmacology 45:231 241.
33. Shehab S, McGonigle D, Hughes DI, Todd AJ, Redgrave P 2005) Anatomical evidence for an anticonvulsant relay in the rat ventromedial medulla. Eur J Neurosci 22:1431 1444.
34. Shen KZ, North RA 1992) Substance P opens cation channels and closes potassium channels in rat locus coeruleus neurons. Neuroscience 50:345 353.
35. Stenfors C, Srinivasan GR, Theodorsson E, Mathe AA 1992a) Electroconvulsive stimuli and brain peptides: effect of modification of seizure duration on neuropeptide Y, neurokinin A, substance P and neurotensin. Brain Res 596:251 258.
36. Stenfors C, Theodorsson E, Mathe AA 1992b) Brain neuropeptides: changes by treatment with the convulsants pentylenetetrazole and bicuculline. Prog Neuropsychopharmacol Biol Psychiatry 16:747 753.
37. Striano P, Striano S 2008) Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today (Barc) 44:353 368.
38. White HS 2003) Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 (suppl 7 2 8.
39. Zachrisson O, Lindefors N, Brene S 1998) A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res Mol Brain Res 60:291 295.